• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • CRO Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Trending
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • CRO Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

RNA interference (RNAi)

Bunch of wooden blocks with question marks on them
Research

Federal mRNA vax grant cuts includes unrelated project

Tiba Biotech's siRNA flu therapeutic was included in the BARDA mRNA vaccine cuts for unclear reasons.
Darren Incorvaia Aug 7, 2025 2:20pm
Sanofi

Sanofi pens $395M China pact for Arrowhead metabolic med

Aug 1, 2025 7:21am
Photo of Wall Street street sign with american flags in the background

Arrowhead reassures investors about pact with troubled Sarepta

Jul 23, 2025 10:13am
blueprint city rendering

Biogen blueprints $1B CNS deal with RNAi biotech

May 27, 2025 10:55am
Kidneys brightly lit

Arrowhead shares ‘select’ data for RNAi asset in kidney trial

Mar 10, 2025 11:55am
scary haunted house at night

Alnylam abandons clinical-stage Type 2 diabetes asset

Oct 31, 2024 10:27am

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2025 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings